Use of Everolimus in De Novo Renal Recipients: Initial Experience in the Greek Population

Transplantation Proceedings

Volumn 40, Issue 9, 2008, Pages 3166-3169

  Papanikolaou, V ^a   Vrochides, D ^a   Margari, P ^a   Imvrios, G ^a   Papagiannis, A ^a   Giakoustidis, D ^a   Fouzas, I ^a   Antoniadis, N ^a   Ouzounidis, N ^a   Ntinas, A ^a   Vergoulas, G ^a   Miserlis, G ^a   Solonaki, F ^a   Takoudas, D ^a  

^a Aristotle University Medical School   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BASILIXIMAB; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; ATELECTASIS; CATHETER INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG USE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GREECE; HUMAN; HYPERTENSION; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; THROMBOCYTOPENIA; URINARY TRACT INFECTION; WOUND DEHISCENCE; WOUND INFECTION;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; CREATININE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 56049123703     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.09.038     Document Type: Article

References (8)

1. Lorber M.I., Mulgaonkar S., Butt K.M., et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 80 (2005) 244
2. Johnson R.W., Kreis H., Oberbauer R., et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72 (2001) 777
3. Chapman T.M., and Perry C.M. Everolimus. Drugs 64 (2004) 861
4. Vitko S., Tedesco H., Eris J., et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 4 (2004) 626
5. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31
6. Vitko S., Margreiter R., Weimar W., et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 5 (2005) 2521
7. Pascual J. [Everolimus: immunosuppression with antilymphoproliferative therapy]. Nefrologia 24 (2004) 112
8. Pape L., Ahlenstiel T., Ehrich J.H.H., et al. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A. Pediatr Transplant 11 (2007) 291